Extended Data Fig. 7: IL-10–Fc potentiates adoptive T cell transfer therapies to eradicate established solid tumors without overt toxicity.

a, Shown are individual tumor growth curves of the therapy experiments in Fig. 5a. Indicated are numbers of long-term surviving mice among the total number of mice in the group. b-c, The experimental setting was the same as that described in Fig. 1. b, Ratio of counts of CD8⁺ T cells to regulatory T cells (Tregs) in tumors in different treatment groups. c, Frequencies of granzyme B⁺IFNγ⁺TNFα⁺ polyfunctional CD8⁺ T cells among total CD8⁺ TILs. Data are one representative of three independent experiments (n = 5 independent animals). d-h, Thy1.2⁺ C57BL/6 mice were inoculated s.c. with B16F10 melanoma cells (5 × 10⁵) on day 0, and received i.v. adoptive transfer of activated Thy1.1⁺ PMEL CD8⁺ T cells (5 × 10⁶) on day 6, followed by p.t. administration of IL-10–Fc (20 µg) or PBS control every 4 days until day 18. d, Experimental timeline. e-h, Shown are average tumor growth curves (e), survival curves (f), and individual tumor growth curves (g, h) of each treatment group. Indicated are numbers of long-term surviving mice out of the total numbers in the group. Data are representative of two independent experiments (n = 10 independent animals). i-k, The experimental setting was the same as that described in Fig. 1. On day 14, mice were killed and serum samples were collected for analysis. Shown are relative body weight (i), serum alanine transaminase (ALT, j) and aspartate transaminase (AST, k) levels of the treated mice. Shown are pooled data of two independent experiments (n = 10 independent animals). All data represent the mean ± s.e.m. and are analyzed by one-way ANOVA and Tukey’s test; NS, not significant (P > 0.05).

Source data